Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 8.01
The filing discloses two material transactions: (1) a 20-year lease agreement with Anthropic generating approximately $19 billion in contracted revenue over the initial term, and (2) the sale of TeraWulf's 50.1% ownership interest in the Abernathy Joint Venture to Fluidstack for approximately $530 million in aggregate consideration. Both transactions are significant capital events that materially affect the company's financial position, revenue visibility, and strategic direction. The Abernathy sale is explicitly a disposition of equity interests, and the Anthropic lease represents a major long-term revenue commitment that would affect investor assessment of the registrant's future cash flows and growth prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 7.01
Element Solutions Inc. entered into a definitive Agreement and Plan of Merger on July 6, 2026, whereby Solstice Advanced Materials will acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion (including assumption of net debt). The transaction structure provides $10.00 cash plus 0.500 Solstice shares per Element share, with expected closing in H1 2027, subject to customary conditions including regulatory and shareholder approvals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 2.01
Liminatus Pharma completed the acquisition of InnocsAI LLC on July 2, 2026, pursuant to an Amended and Restated Merger Agreement entered into on June 29, 2026. The transaction involved approximately 1.6 billion shares of merger consideration comprising 19.99% common stock and Series A Non-Voting Convertible Preferred Stock, along with registration rights and non-compete agreements.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The exhibit announces the appointment of Rob Slack, PhD, as Chief Scientific Officer of Vicore Pharma, effective immediately. This is a material executive appointment at a clinical-stage biopharmaceutical company, where the Chief Scientific Officer role is critical to research strategy and pipeline development. The disclosure also notes that the prior CSO, Johan Raud, is transitioning to Senior Advisor, which is a secondary departure element but the primary disclosed action is Slack's appointment to the CSO position.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 5.02
Sarkees John Nahas, a member of the Company's Board of Directors, resigned effective July 1, 2026. The disclosure explicitly states the resignation date and confirms no disagreement with the Company, which is a standard departure disclosure. Board composition changes are material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
This Item 5.07 filing discloses the results of an extraordinary general meeting of shareholders held on July 6, 2026, where Spring Valley Acquisition Corp. III shareholders voted on seven proposals, including approval of a business combination with General Fusion Inc., continuation from Cayman Islands to British Columbia, governance amendments, and director elections. All proposals were approved with detailed voting tallies provided for each. This is a classic shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-06
Item 3.01
CytoSorbents received a written notice from Nasdaq on June 29, 2026, that it failed to comply with Nasdaq Listing Rule 5550(b)(2) due to its Market Value of Listed Securities falling below the $35 million minimum required for continued listing on the Nasdaq Capital Market. The company has been given a 180-day grace period (until December 28, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification and potential loss of listing. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 8.01
ClearSign Technologies filed a prospectus supplement on July 6, 2026 to recommence an "at the market" offering under which it may sell up to $6,875,000 in common stock shares pursuant to an ATM agreement with H.C. Wainwright & Co. This is a classic dilutive equity issuance under Rule 415, material to investors as it signals potential shareholder dilution and the company's capital-raising needs.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-07-06
Item 5.07
Two Harbors' stockholders voted to approve the merger with CrossCountry Mortgage at a special meeting held on July 2, 2026, with 54,297,767 votes in favor and 23,570,833 against. The merger consideration is $12.00 per share in cash plus a pro-rated stub dividend, and completion is now contingent on satisfaction of remaining regulatory approvals.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
The filing discloses shareholder approval and effective implementation of amendments to the Company's Amended and Restated Memorandum of Association and Articles of Association, including a doubling of authorized share capital from CI$12.5 million to CI$25 million and amendments regarding share repurchase authority and treasury share treatment. While shareholder vote results are typically classified as shareholder_vote_results, this filing emphasizes the effective implementation of the governance amendments themselves rather than reporting the vote outcome (which was disclosed in the Prior Form 8-K of June 5, 2026). The material governance changes—particularly the doubling of authorized shares and new share repurchase authority—constitute a governance event affecting the company's capital structure and shareholder rights.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 5.02
Steven Kemps, Executive Vice President and Chief Legal Officer, notified the Company on July 1, 2026 of his decision to retire effective December 31, 2026. The Company is launching a search for his successor.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-06
Item 1.01
Meridian3 Industrials Acquisition Corp consummated its IPO on July 1, 2026, raising $201.25 million in gross proceeds through entry into multiple material definitive agreements including underwriting, warrant, registration rights, and private placement agreements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The Company completed an unregistered private placement of 5,500,000 warrants to the Sponsor and Cantor Fitzgerald at $1.00 per warrant, generating $5.5 million in gross proceeds, with the warrants exercisable into Class A Ordinary Shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Five individuals—Professor Dr Sir Ralf Speth, Dr. John Llewellyn, Steven G. Osgood, Hideyuki Nakashima, and Steven Robert Armstrong—were appointed to the board of directors effective July 1, 2026 in connection with the IPO, with four designated as independent directors and committee assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 1.01
Optimum Communications entered into a Second Amended and Restated Credit Agreement establishing an incremental term loan commitment of $250 million with a fixed 9.000% interest rate maturing November 25, 2028.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-06
EX-99.1
Dylan Marx has been appointed as Chief Executive Officer of Recurrent Energy, the Company's global project development subsidiary, effective immediately. While Ismael Guerrero's departure from the CEO role is also disclosed, the principal action announced is the appointment of Marx to lead a material subsidiary. The filing emphasizes Marx's qualifications and the seamless transition plan, consistent with an executive appointment disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 2.02
This Item 2.02 disclosure presents preliminary unaudited estimates of Rivian's Q2 2026 financial results, including total consolidated revenues (estimated $1.55–$1.65 billion, up from $1.30 billion in Q2 2025) and cash position ($5.3 billion as of June 30, 2026). The disclosure explicitly states these are "preliminary estimates of selected financial information" and explains the drivers of revenue growth (increased vehicle deliveries, higher commercial van mix, software services, and regulatory credits). This is a classic earnings release format—preliminary financial results disclosed via 8-K Item 2.02 ahead of full quarterly filings—and is material to investors assessing the company's operational performance and financial trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Element Solutions Inc entered into an Agreement and Plan of Merger with Solstice Advanced Materials Inc on July 6, 2026, whereby Element Solutions will merge with Solstice subsidiaries in a two-step transaction, with Element Solutions stockholders receiving 0.500 shares of Solstice Common Stock and $10.00 cash per share.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-06
Item 5.02
Element Solutions memorialized a letter agreement with John E. Capps, former Executive Vice President, General Counsel and Secretary, confirming his continued entitlements under his Change in Control Agreement, including receipt of annual bonus and severance at levels to which he was entitled in connection with the proposed merger.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
Item 5.03
This disclosure describes a 5-for-1 reverse stock split effected through amendments to the Declaration of Trust, reducing outstanding shares from ~647.64 million to ~129.53 million. While a reverse split is a governance/structural action (amendment to articles), it is material to investors as it affects share count, trading mechanics, and potential delisting implications. The event does not fit the specific governance categories (exec appointment/departure, compensation, shareholder vote results) but is clearly a material governance matter warranting disclosure under Item 5.03.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-06
Item 1.01
GridAI Technologies entered into a securities purchase agreement on July 1, 2026, to sell 664,598 shares of common stock, pre-funded warrants, and common stock purchase warrants for approximately $8.5 million in gross proceeds through a private placement relying on Section 4(a)(2) exemption. The transaction includes substantial warrant components (pre-funded warrants exercisable at $0.0001 and common warrants exercisable at $4.47) that significantly increase dilution potential.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-06
Item 1.01
Arbor Realty Trust completed the issuance and sale of $375 million aggregate principal amount of 6.25% Convertible Senior Notes due 2029 on July 6, 2026. The convertible notes represent a material creation of a new direct financial obligation, with proceeds to be used for redemption of existing debt and share repurchases.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-06
EX-99.1
Canaan announced completion of a transfer from Nasdaq Global Market to Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 for 30 consecutive business days. The company received a non-compliance notice on January 14, 2026, and has applied for an additional 180-day compliance period. This disclosure directly addresses delisting risk and the company's efforts to regain compliance with continued listing standards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Hope Lundt was appointed to the Board of Directors of EWSB Bancorp, Inc. and its subsidiary on July 1, 2026, and assigned to the Audit Committee and Governance and Nominating Committee. This is a clear director appointment, the principal disclosed action. The disclosure of standard non-employee director compensation arrangements is incidental to the appointment itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 2.02
This is a straightforward earnings release disclosing Q1 2026 financial results for Exyn Technologies. The filing explicitly states "On July 6, 2026, Exyn Technologies, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026" and furnishes the press release as Exhibit 99.1. The exhibit contains detailed financial metrics including revenue ($1.19M), gross profit ($0.50M), operating expenses ($3.38M), and net loss ($3.24M), along with strategic highlights including the company's recent IPO completion. This is a material disclosure affecting investor assessment of the registrant's financial performance and operational status.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-06
EX-99.1
Standard Lithium disclosed the issuance of 3,139,330 common shares under its at-the-market (ATM) equity program during Q2 2026, generating gross proceeds of US$11.3 million. ATM offerings are unregistered equity issuances that dilute existing shareholders and are material capital-raising events, particularly for development-stage companies like Standard Lithium.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 8.01
The filing discloses a material regulatory setback to a pending merger transaction: the New Mexico Public Regulation Commission issued a final order on July 2, 2026, voiding the $400 million PIPE Transaction (equity financing for the Merger) as undertaken without prior NMPRC authorization, imposing a $300,000 aggregate penalty, and requiring a compliance report within 45 days. The NMPRC also stayed the procedural schedule for the Merger Application pending review of the compliance filing. This regulatory action materially affects the consummation and financing of the Merger between TXNM and Blackstone Infrastructure Partners, making it a significant M&A development.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
Barnwell Industries held its Annual Meeting of Stockholders on June 29, 2026, at which shareholders voted on six proposals: director elections, amendments to the 2018 Equity Incentive Plan, ratification of prior equity awards, advisory say-on-pay vote, frequency of future say-on-pay votes, and ratification of the independent auditor (Weaver & Tidwell, L.L.P.). All proposals passed.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release announces the extension of a time charter contract for the M/T Briolette with Aramco Trading for 35 months at US$37,700 per day, expected to generate approximately US$39 million in gross revenue. While the disclosure is operational in nature (a material commercial contract), it does not fit the specific event types of debt issuance, M&A activity, or other named categories. The announcement is material to investors as it demonstrates significant contracted revenue backlog (exceeding $500 million), extends charter coverage through 2028-2029, and provides earnings visibility—metrics that would affect a reasonable investor's assessment of the company's financial position and operational strength.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Crinetics Pharmaceuticals entered into a definitive merger agreement with Vertex Pharmaceuticals on July 6, 2026, under which Vertex will acquire Crinetics for $85.00 per share in cash, representing approximately $10.0 billion in total equity value (or $8.8 billion net of cash). The transaction is expected to close in Q3 2026, subject to regulatory and shareholder approvals, and adds significant commercial and pipeline assets including PALSONIFY and atumelnant with approximately $5 billion peak sales potential to Vertex's portfolio.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-06
EX-99.1
This press release discloses the results of Inventiva's Combined Shareholders' General Meeting held on June 30, 2026, presenting detailed voting outcomes for 40 ordinary and extraordinary resolutions. The document explicitly states "All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 31st resolution," and provides comprehensive vote tallies including approval percentages, abstentions, and quorum information. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, material to investors as it confirms shareholder approval of governance matters including compensation policies and board-related decisions.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
EX-99.1
ING announced a strategic investment acquiring approximately 40% stake in Singular Bank, a leading Spanish wealth manager with €19 billion in client invested assets. The transaction represents a material acquisition of a significant ownership stake in an independent financial institution, fitting squarely within the M&A activity category. The press release explicitly describes this as a "strategic investment" and "acquisition of a stake," with closing expected in Q1 2027 subject to regulatory approvals, and CEO commentary emphasizing it as a key strategic move to accelerate growth in Private Banking and Wealth Management.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
EX-99.1
This press release announces the launch of Intermap's AI-enabled Orthorectification Service on the UP42 platform, a new commercial product offering that expands the company's role in the satellite imagery ecosystem. The disclosure describes a material operational and strategic development—the introduction of a scalable intelligence service leveraging the company's proprietary 3D terrain data—that would affect a reasonable investor's assessment of the company's growth prospects and market positioning in the expanding commercial space and Earth observation markets.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses a scheduled earnings release announcement for PennantPark Floating Rate Capital Ltd.'s third fiscal quarter ended June 30, 2026, to be reported on August 10, 2026. The press release explicitly states the company "announced that it will report results for the third fiscal quarter ended June 30, 2026" and includes details of a conference call to discuss financial results. This is a material disclosure of quarterly earnings results, typical of Item 7.01 Regulation FD disclosures announcing earnings dates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses a press release announcing PennantPark Investment Corporation's scheduled earnings release for the third fiscal quarter ended June 30, 2026, with results to be reported on August 10, 2026, and a conference call scheduled for August 11, 2026. Although this is technically an announcement of when earnings will be released rather than the earnings themselves, the core disclosure is the earnings announcement, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-06
Item 8.01
The press release announces that Brookfield Asset Management will host a second quarter 2026 results conference call on August 5, 2026, with results to be released that morning prior to 7:00 a.m. ET. This is a standard earnings announcement disclosing the timing and logistics for the release of quarterly financial results, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-06
EX-99.1
The exhibit discloses material equity issuance activity under the Company's at-the-market (ATM) program, which generated approximately US$2.1 million in gross proceeds through the issuance of 3,009,295 Common Shares during Q2 2026 at a weighted average price of US$0.68 per share. The ATM program itself is authorized for up to US$25 million. This represents a dilutive equity issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure. While the exhibit also mentions employee share purchase and director DSU grants, the primary material disclosure is the ATM equity offering activity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release discloses material clinical and pipeline progress across Molecular Partners' Radio-DARPin therapeutic program, including: ongoing Phase 1/2a dosing of MP0712 (DLL3-targeted, 212Pb-based) with initial data expected within months; initiation of compassionate care work in South Africa with MP0714 (225Ac-loaded DLL3 Radio-DARPin); planned first-in-human imaging for MP0726 (MSLN-targeted) in H2 2026; and two planned INDs in 2027. While not a discrete M&A, financing, or governance event, these clinical milestones and pipeline expansions materially advance the company's drug development strategy and would affect a reasonable investor's assessment of near-term catalysts and long-term value creation.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
EX-99.1
ZIM discloses an update on its "previously announced merger agreement with Hapag-Lloyd" and states the company "continues to act in accordance with the agreement and in ongoing collaboration with the relevant state authorities as part of the regulatory review process." This is a material acquisition/merger activity (Item 1.01 or 2.01 equivalent) that would materially affect a reasonable investor's assessment of the registrant's future, even though the update itself is procedural in nature.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 92%
filed 2026-07-06
The 6-K discloses results of Tower Semiconductor's annual general meeting held July 2, 2026, where shareholders voted on multiple proposals. The filing explicitly states that "all proposals were approved at the meeting by the requisite majority" except Proposal 3 (amended compensation policy), which failed. This is a direct shareholder vote result disclosure, matching the shareholder_vote_results event type. The failure of the compensation policy proposal is material to investors assessing governance and executive compensation practices.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The exhibit discloses the appointment of Yoav Har-Even as an independent director of Innoviz Technologies Ltd. effective July 5, 2026, to fill a newly vacant seat. This is a clear executive/governance appointment event. While the filing also mentions James Sheridan's resignation, the principal disclosed action is the appointment of a new director with significant qualifications (former CEO of Rafael Advanced Defense Systems, retired Major General). Board composition changes affecting independent director status are material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 3.02
IGC Pharma issued 4,274,853 shares of common stock to executive officers (CEO Ram Mukunda and CFO Claudia Grimaldi) in a debt-for-equity conversion, canceling $1,154,210 in outstanding obligations. The unregistered private placement under Section 4(a)(2) of the Securities Act represents a material dilutive equity transaction affecting shareholder ownership structure and executive compensation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 2.03
UY Scuti Acquisition Corp. created a direct financial obligation by borrowing $450,000 from Isdera HK Limited (an affiliate of Isdera Group) to extend its trust account deadline, with the Company expecting to issue a promissory note to the lender.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 8.01
The Company extended the deadline to consummate an initial business combination with Isdera Group Limited following a deposit to the Trust Account, with a registration statement to be filed in connection with the pending merger transaction.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-06
The filing discloses issuance of 1,645,353 restricted shares totaling ¥10.98 billion to directors, corporate executive officers, and subsidiary executives under SMFG's stock compensation plans. This is a material compensatory arrangement involving equity grants with performance conditions and vesting schedules, filed pursuant to Japanese securities law requirements and incorporated by reference into SMFG's Form F-3 registration statement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 1.01
Scilex entered into a binding term sheet with iHolding Group LLP for a $100 million strategic investment through the private placement of approximately 6.67 million newly issued shares of common stock at $15.00 per share, subject to customary closing conditions including stockholder approval and regulatory approvals.
View raw filing on EDGAR →
8-K
Governance Other
confidence 82%
filed 2026-07-06
Item 5.03
USA Compression Partners, LP redomiciled from Delaware to Texas on July 6, 2026, pursuant to board and Conflicts Committee approval. The conversion materially modified unitholder rights, fiduciary duty protections, liability limitations, distribution restrictions, and forum selection provisions under the Texas Business Organizations Code versus Delaware law, representing a material governance restructuring affecting investor protections and economic interests.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-07-06
Item 8.01
Invivyd received a Notice of Termination of the Emergency Use Authorization (EUA) for PEMGARDA from the FDA, effective June 29, 2027, following HHS's announcement of termination of the COVID-19 EUA declaration. This is a material regulatory event that eliminates the company's primary authorized product and revenue source, but it is fundamentally a regulatory/legal matter rather than a financial restatement, going-concern issue, or other specific category. The company is in dialogue with the FDA regarding next steps, including potential Biologics License Application (BLA) submission, but the immediate event is the loss of regulatory authorization.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-06
Item 8.01
Strategy Inc. disclosed an $8.32 billion loss on digital assets in Q2 2026, including a significant unrealized loss requiring a full valuation allowance against deferred tax benefits. The disclosure also covers the company's bitcoin monetization strategy to fund its USD reserve.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-06
Item 8.01
Broadcom and Apple have entered into new multi-year long-term agreements for Broadcom to develop and supply custom ASIC silicon products through 2031, representing an expansion of their existing technology collaboration. This is a material strategic partnership and supply agreement that would affect investor assessment of Broadcom's revenue visibility and competitive positioning, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types—making it an operational/strategic business event.
View raw filing on EDGAR →